Drug reference
Fremanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, inhibiting the function of CGRP at its receptor, and thereby preventing migraine attacks.
PDF page 521
Prophylaxis of migraine [in patients who have at least 4 migraine days per month] (initiated by a specialist) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 225 mg once a month, alternatively 675 mg every 3 months, review treatment within first 3 months and regularly thereafter
PDF page 521
Major cardiovascular disease (no information available)
PDF page 521
Fremanezumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1; manufacturer advises to record the brand name and batch number after each administration. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2-8°C) and protect from light—consult product literature for further information regarding storage outside refrigerator.
PDF page 521
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2226 The Scottish Medicines Consortium has advised (January 2020) that fremanezumab (Ajovy ®) is accepted for restricted use within NHS Scotland for the prophylaxis of chronic and episodic migraine in adults who have had prior failure on three or more migraine preventive treatments. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 521
Hypersensitivity
PDF page 521
Manufacturer advises avoid—limited information available.
PDF page 521
Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breast- feeding only if clinically needed.
PDF page 521
Manufacturer advises injection into the abdomen, thigh or upper arm. Patients may self-administer Ajovy ® after appropriate training in subcutaneous injection technique.
PDF page 521
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Edetic acid (edta), polysorbates, sucrose A ▶Ajovy (Teva UK Ltd) Fremanezumab 150 mg per 1 ml Ajovy 225mg/1.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection P Nervous system £450.00
PDF page 521
Self-administration Manufacturer advises patients and their carers should be given training in subcutaneous injection technique if appropriate.
PDF page 521
225 mg once a month, alternatively 675 mg
First-line fragment. Read the complete Indications and Dose section above.
PDF page 521
